United States Patent 4,031,894 (Scopolamine Transdermal Therapeutic Bandage): Scope, Claim Map, and US Patent Landscape

Executive summary: US Patent 4,031,894 claims a scopolamine-base transdermal bandage using a sandwich laminate with (i) an impermeable backing, (ii) a reservoir gel containing scopolamine base in mineral oil/polyisobutene, (iii) a microporous membrane that meters release at ~0.3 to 15 μg/hr, and (iv) a contact adhesive also formulated with mineral oil/polyisobutene and containing ~10 to 200 μg scopolamine base per cm². Dependent claims narrow to strippable impermeable release liner, specific patch area, specific mineral oil/polyisobutene weight ratios and polyisobutene molecular-weight blends, microporous membrane porosity/tortuosity/thickness, and specific backing materials. The claim architecture is structural and formulation-defined (materials, ranges, and microstructural membrane parameters), making design-around through alternative metering mechanisms, non-matching gel binders, or non-matching release-constant structures the core strategic question.

What does US Patent 4,031,894 claim for a scopolamine transdermal bandage system?

Core independent claim (Claim 1) in plain technical terms: A transdermal therapeutic system “in the form of a bandage” that administers scopolamine base through unbroken skin for prolonged time, with:

Sandwich-type laminate with four key lamina elements:
- (a) Backing lamina: substantially impermeable to scopolamine base; one face is the top of the bandage.
- (b) Scopolamine base reservoir lamina adjacent to the backing lamina:
  - contains 0.2 to ~3 mg scopolamine base dispersed in a gelled mixture of:
    - mineral oil (about 10 to about 100 cp at 25°C), and
    - polyisobutene.
- (c) Microporous membrane lamina adjacent and below the reservoir:
  - scopolamine base is released through this membrane at a substantially constant rate of ~0.3 to ~15 μg/hr.
- (d) Contact adhesive lamina adjacent and below the microporous membrane:
  - affixes to skin,
  - contains ~10 to ~200 μg scopolamine base per cm² dispersed in a gelled mixture of mineral oil + polyisobutene.
Product-mechanism coupling: The same overall system requires both:
- a metering membrane (microporous) that yields the constant release rate, and
- an adhesive layer loaded with scopolamine base and gelled with mineral oil/polyisobutene.

Claim 1 “must-have” elements that define infringement territory

A US court would typically view Claim 1 as requiring all structural and quantitative limitations together. Practically, that means a competing bandage is at highest risk if it includes all:

Scopolamine base (not scopolamine salts, not different active)
Unbroken skin transdermal delivery
Backed laminate with impermeable backing
Reservoir gel: scopolamine base 0.2–3 mg, dispersed in mineral oil (10–100 cp at 25°C) + polyisobutene
Microporous membrane below reservoir
Release rate: 0.3–15 μg/hr at “substantially constant rate”
Skin-contact adhesive that:
- contains scopolamine base 10–200 μg/cm², and
- is gelled with mineral oil + polyisobutene

How do the dependent claims narrow the scope of US 4,031,894?

Claim 2: Is a strippable release liner required?

Adds:

Strippable coating lamina adjacent below the contact adhesive,
Substantially impermeable to adhesive components,
Adapted to be stripped off before application.

Design-around leverage: If a competitor uses a different liner strategy (e.g., water-soluble or incompatible coating system, or a different adhesive-release interface), Claim 2 becomes a focal point only where Claim 1 is otherwise met.

Claim 3: Is patch size limited to a small area?

Effective surface area: ~0.5 to 4 cm².

Claim 4: Are mineral oil and polyisobutene weight fractions limited?

Mineral oil 35% to 65% by weight
Polyisobutene 35% to 65% by weight

Claims 5–6: Does the claim require a polyisobutene molecular-weight blend?

Claim 5 requires a blend of:
- first polyisobutene: viscosity average molecular weight 35,000–50,000
- second polyisobutene: viscosity average molecular weight 1,000,000–1,500,000
Claim 6 further requires specific weight distribution:
- mineral oil 35–65 wt%
- first polyisobutene 10–40 wt%
- second polyisobutene 20–40 wt%

Practical implication: These claims are narrow but highly technical. They can be used to argue specificity in prior art and to support infringement if the accused composition uses the same binder architecture.

Claims 7–9: Are microporous membrane physical parameters limited?

Claim 7 sets microporous membrane:
- porosity ~0.1 to 0.85
- tortuosity ~1 to 10
- thickness ~10^-3 to 10^-2 cm
Claim 8: membrane made of polypropylene
Claim 9: effective area ~0.5–4 cm² and microporous membrane polypropylene

Claim 10: Is the backing material specified?

Backing lamina made of aluminized polyethylene terephthalate.

Claims 11–12: Are release rate windows and per-area loading fixed?

Claim 11:
- constant rate ~5 to 15 μg/hr
- adhesive loading ~50 to 150 μg/cm²
Claim 12:
- constant rate ~3 to 10 μg/hr
- adhesive loading ~50 to 150 μg/cm²

Note on claim structure: These are not purely quantitative “ranges.” They interlock with the system architecture from Claim 1.

What is the likely practical “claim map” for US 4,031,894 across patch layers?

Patch laminate element	Claim language scope	Quantitative limits in 4,031,894	Highest-risk corresponding design facts to test
Backing lamina	substantially impermeable to scopolamine base	(no numeric)	backing permeability, presence of aluminum-PET
Reservoir lamina	reservoir adjacent to backing	scopolamine base 0.2–3 mg; gelled mineral oil + polyisobutene	total drug in reservoir, gel binder identity and oil viscosity
Metering layer	microporous membrane adjacent below reservoir	release 0.3–15 μg/hr “substantially constant”	membrane microporosity, thickness, tortuosity, material; measured release
Adhesive lamina	contact adhesive adjacent below microporous membrane	scopolamine base 10–200 μg/cm² in gelled mineral oil + polyisobutene	adhesive drug loading per area and binder formulation
Liner (if used)	strippable coating lamina	impermeable to adhesive components	liner type and whether substantially impermeable
Patch area	effective surface area	0.5–4 cm²	total area used and effective area definition
Binder ratios	mineral oil/polyisobutene composition	mineral oil 35–65 wt%, PIB 35–65 wt%	exact wt% ranges
PIB molecular-weight blend	specific dual PIB MW	35k–50k plus 1M–1.5M	MW distribution selection and blend proportions
Membrane physical parameters	microporous membrane properties	porosity 0.1–0.85, tortuosity 1–10, thickness 10^-3–10^-2 cm	measured membrane specs and material choice
Backing material (narrow)	specific backing chemistry	aluminized PET	backing substrate identity

What patents likely formed the prior art and competitive landscape around US 4,031,894’s claim structure?

US 4,031,894 sits in the technical space of early transdermal scopolamine delivery systems that use:

polymeric/hydrocarbon gels (mineral oil and PIB appear central here),
metering membranes with controlled release rates, and
adhesive drug loading for skin contact.

In litigation and freedom-to-operate analyses, the competitive landscape is typically segmented into at least four adjacent categories, each with distinct design-around pathways:

Different active form
- scopolamine base vs salts vs other anticholinergics. Claim 1 is anchored on “scopolamine base.”
Different metering concept
- membranes with different polymer types, non-microporous release control (e.g., diffusion-controlled matrices without distinct microporous membrane), or reservoir-in-adhesive architectures.
Different gel binders
- replacing mineral oil + PIB with other tackifiers, elastomers, or hydrogel systems.
Different release rate and loading architecture
- changing the per-area loading and release rate windows, even while maintaining similar materials.

Important analytic consequence: US 4,031,894’s claim set is both structural (lamina types) and compositional (mineral oil viscosity window, PIB MW blend, per-area loading), which makes it harder to infringe with a “generic” transdermal adhesive patch unless the formulation and layer engineering are close.

How strong is the patent estate implied by the claim set for enforceability?

Even without a full file wrapper here, the claim set indicates the invention’s perceived value was in specific, measurable parameters. That tends to strengthen enforceability because:

release rate is defined as a measurable constant range,
microporous membrane porosity, tortuosity, and thickness are defined,
reservoir drug load and adhesive drug load are defined, and
binder composition and PIB MW blend are defined in narrow ranges.

Strength drivers (relative):

Multiple independent “attack surfaces” for infringement: membrane characteristics, release rate, adhesive loading, and binder MW blend.
Narrow dependent claims that can be used in layered infringement theories if a challenger overlaps any sub-range.

Strength reducers (relative):

Many dependent claims are highly specific; a competitor can avoid infringement by moving outside one numeric boundary (e.g., different PIB MW blend or different mineral oil viscosity).

What design-around routes follow directly from Claim 1 and dependent claim narrowing?

1) Break the “microporous membrane releases at a constant rate” requirement

Use a non-microporous diffusion controlling layer (or a matrix with no discrete microporous membrane).
Use a membrane with substantially different porosity/tortuosity/thickness outside Claim 7.
Use a different membrane material outside Claim 8 (polypropylene), while staying within comparable release performance.

2) Change binder chemistry away from mineral oil + polyisobutene

Replace mineral oil with another oil or polymerizable component not meeting “10 to 100 cp at 25°C.”
Replace PIB with a different tackifying polymer (or add co-polymers not matching the required PIB blend).

3) Change loading architecture

Adjust scopolamine base per area on the adhesive away from 10–200 μg/cm² (Claim 1) or away from 50–150 μg/cm² (Claims 11–12).
Adjust reservoir drug mass away from 0.2–3 mg per patch (Claim 1).

4) Remove or change adhesive layer architecture

Use a backing and reservoir but avoid scopolamine base in the adhesive lamina (e.g., drug only in reservoir, adhesive being essentially drug-free).
Alter adhesive formulation so it is not gelled with mineral oil + PIB.

5) Avoid the claimed liner configuration (if already at Claim 2 stage)

Use a liner that is not “substantially impermeable” to adhesive components or is not “strippable” as claimed.

Which specific claim features are most likely to be litigated in a transdermal scopolamine dispute?

Release-rate measurement (substantially constant 0.3–15 μg/hr; narrower 3–10 and 5–15 windows)
Microporous membrane engineering (porosity/tortuosity/thickness and polypropylene material)
Per-area adhesive drug loading (10–200 μg/cm² and 50–150 μg/cm² in narrower claims)
Binder identity and MW blend (mineral oil viscosity window; PIB molecular-weight blend and wt% fractions)

These are the variables that map most cleanly to analytical testing: membrane microscopy/porosimetry, adhesive extraction assays, and in vitro release testing.

Key Takeaways

US 4,031,894 claims a scopolamine base transdermal bandage with a sandwich laminate: impermeable backing, scopolamine-loaded mineral oil/PIB gel reservoir, microporous membrane metering delivering ~0.3–15 μg/hr, and a scopolamine-loaded mineral oil/PIB adhesive delivering skin contact.
Dependent claims tighten scope around: release liner, patch area (0.5–4 cm²), binder wt% ranges, PIB MW blend, microporous membrane porosity/tortuosity/thickness and polypropylene, and specific backing material (aluminized PET).
Claim construction leverage is highest on measurable features (release rate windows, membrane porosity/tortuosity/thickness, and drug loading per cm²), which also define the clearest design-around paths (alter metering layer, alter binder system, alter loading and release ranges).

FAQs

1) What release rate range does US 4,031,894 require for infringement?
Claim 1 requires ~0.3 to ~15 μg/hr at a substantially constant rate; narrower dependent claims recite 3–10 μg/hr or 5–15 μg/hr.

2) Does US 4,031,894 require scopolamine base in both the reservoir and adhesive?
Yes. Claim 1 requires scopolamine base in the reservoir lamina and also requires scopolamine base in the contact adhesive lamina at 10–200 μg/cm².

3) What microporous membrane properties are claimed?
Porosity ~0.1–0.85, tortuosity ~1–10, thickness ~10^-3–10^-2 cm, with an optional narrower limitation to polypropylene.

4) Is the adhesive liner part of the main claim?
No. The strippable impermeable liner is in Claim 2. Claim 1 does not require it.

5) What binder specificity is required in the narrowest composition claims?
Claim 5–6 require a blend of polyisobutene with viscosity-average molecular weights of 35,000–50,000 and 1,000,000–1,500,000, with mineral oil and PIB in defined wt% ranges.

References

United States Patent No. 4,031,894, “Therapeutic system for administering scopolamine base through unbroken skin.”

Details for Patent: 4,031,894

Summary for Patent: 4,031,894